Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.34
+0.13 (2.09%)
At close: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Taysha Gene Therapies Employees
Taysha Gene Therapies had 99 employees as of December 31, 2025. The number of employees increased by 26 or 35.62% compared to the previous year.
Employees
99
Change (1Y)
26
Growth (1Y)
35.62%
Revenue / Employee
$75,465
Profits / Employee
-$1,311,879
Market Cap
2.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 99 | 26 | 35.62% |
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Lakefront Biotherapeutics NV | 558 |
| Syndax Pharmaceuticals | 298 |
| Zymeworks | 243 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
| Absci | 140 |
| AnaptysBio | 104 |
TSHA News
- 1 day ago - Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - GlobeNewsWire
- 1 day ago - Taysha Gene Therapies management to meet with Piper Sandler - TheFly
- 2 days ago - Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00 - TheFly
- 2 days ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 days ago - Taysha Gene Therapies announces $200M common stock offering - TheFly
- 2 days ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 days ago - Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital - TheFly
- 3 days ago - Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital - TheFly